Berbice Capital Management LLC Buys Shares of 1,100 Natera, Inc. (NASDAQ:NTRA)

Berbice Capital Management LLC bought a new stake in Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 1,100 shares of the medical research company’s stock, valued at approximately $174,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Versant Capital Management Inc grew its position in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the last quarter. Quarry LP boosted its position in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the last quarter. Covestor Ltd boosted its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the last quarter. GAMMA Investing LLC boosted its position in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares during the last quarter. Finally, True Wealth Design LLC acquired a new stake in Natera during the third quarter worth approximately $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Up 0.2 %

Natera stock opened at $172.11 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $165.35 and a two-hundred day moving average price of $135.41. The firm has a market capitalization of $22.72 billion, a price-to-earnings ratio of -97.62 and a beta of 1.65. Natera, Inc. has a 52-week low of $62.96 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same period in the previous year, the firm earned ($0.95) EPS. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. Sell-side analysts expect that Natera, Inc. will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NTRA shares. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. The Goldman Sachs Group raised their target price on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Sanford C. Bernstein raised their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Guggenheim raised their target price on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Finally, TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and an average price target of $162.94.

Insider Activity

In related news, insider Solomon Moshkevich sold 1,196 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the transaction, the insider now directly owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. The trade was a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 3,960 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $468,111.60. Following the transaction, the chief executive officer now directly owns 189,762 shares in the company, valued at $22,431,766.02. The trade was a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 224,133 shares of company stock worth $36,830,652 over the last 90 days. 7.60% of the stock is owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.